Skip to main content
. Author manuscript; available in PMC: 2020 Dec 11.
Published in final edited form as: US Endocrinol. 2015 Apr 24;11(1):10–6. doi: 10.17925/use.2015.11.1.10

Table 3:

Pros and Cons of Screening for Type 1 Diabetes Risk

Pros Cons

  • Meets World Health Organization’s screening guidelines48

  • Decrease life-threatening DKA

  • Reliable methods to detect IA

  • Reduced economic burden

  • Clinical prevention trials available

  • Greater understanding of disease natural history from the general population

  • Preventive treatment not yet available

  • Low prevalence in general population

  • Need to repeat IA testing at regular intervals

  • Cost-benefit analysis not yet performed for multiple screenings in an individual

  • Access to healthcare for screening

  • Concerns for increased anxiety based on test results

DKA = diabetic ketoacidosis; IA/s = islet autoantibody/ies.